- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04586231
Une étude du belzutifan (MK-6482) en association avec le lenvatinib versus le cabozantinib pour le traitement du carcinome à cellules rénales (MK-6482-011)
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Berlin, Allemagne, 10117
- Charite Universitaetsmedizin Berlin ( Site 1321)
-
Berlin, Allemagne, 13125
- HELIOS Klinikum Berlin-Buch ( Site 1311)
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Allemagne, 79106
- Klinik fuer Urologie ( Site 1303)
-
Heidelberg, Baden-Wurttemberg, Allemagne, 69120
- NCT-Department of Medical Oncology ( Site 1320)
-
-
Bavaria
-
Nuremberg, Bavaria, Allemagne, 90419
- Klinikum Nuernberg Nord ( Site 1300)
-
-
Hesse
-
Frankfurt am Main, Hesse, Allemagne, 60590
- Universitaetsklinikum Frankfurt ( Site 1301)
-
-
North Rhine-Westphalia
-
Aachen, North Rhine-Westphalia, Allemagne, 52074
- Universitaetsklinikum Aachen AOER ( Site 1317)
-
-
Saarland
-
Homburg/ Saar, Saarland, Allemagne, 66421
- Universitaetsklinikum des Saarlandes ( Site 1305)
-
-
Saxony-Anhalt
-
Halle, Saxony-Anhalt, Allemagne, 06120
- Krankenhaus Martha Maria Halle-Doelau ( Site 1314)
-
-
Thuringia
-
Erfurt, Thuringia, Allemagne, 99089
- Helios Klinikum Erfurt GmbH ( Site 1315)
-
-
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentine, C1120AAT
- Centro de Urología (CDU) ( Site 0803)
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentine, C1280AEB
- Hospital Británico de Buenos Aires-Oncology ( Site 0801)
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentine, C1426ANZ
- Instituto Alexander Fleming ( Site 0800)
-
-
Buenos Aires F.D.
-
Buenos Aires, Buenos Aires F.D., Argentine, C1419AHN
- Asociación de Beneficencia Hospital Sirio Libanés ( Site 0804)
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentine, 2000
- Sanatorio Británico-Clinical Oncology Department ( Site 0802)
-
Rosario, Santa Fe Province, Argentine, S2000DSV
- Sanatorio Parque ( Site 0806)
-
-
-
-
New South Wales
-
St Leonards, New South Wales, Australie, 2065
- GenesisCare North Shore ( Site 4011)
-
-
South Australia
-
Elizabeth Vale, South Australia, Australie, 5112
- Lyell McEwin Hospital ( Site 4004)
-
-
Victoria
-
Frankston, Victoria, Australie, 3199
- Peninsula Health Frankston Hospital ( Site 4001)
-
Melbourne, Victoria, Australie, 3000
- Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 4010)
-
-
-
-
-
Liège, Belgique, 4000
- CHU de Liege ( Site 1102)
-
-
Bruxelles-Capitale, Region de
-
Anderlecht, Bruxelles-Capitale, Region de, Belgique, 1070
- Institut Jules Bordet ( Site 1103)
-
Brussels, Bruxelles-Capitale, Region de, Belgique, 1200
- Cliniques Universitaires Saint Luc - Bruxelles ( Site 1105)
-
-
Hainaut
-
Gilly, Hainaut, Belgique, 6060
- Grand Hopital de Charleroi ( Site 1104)
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgique, 9000
- UZ Gent ( Site 1100)
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgique, 3000
- UZ Leuven ( Site 1101)
-
-
-
-
-
São Paulo, Brésil, 01321-001
- BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0311)
-
São Paulo, Brésil, 01321-001
- Hospital Paulistano - Amil Clinical Research ( Site 0308)
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brésil, 59151600
- Liga Norte Riograndense Contra o Cancer ( Site 0313)
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brésil, 90110-270
- Centro Gaucho Integrado de Oncologia ( Site 0304)
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Arthur J.E. Child Comprehensive Cancer Centre ( Site 0109)
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute ( Site 0111)
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BC Cancer Vancouver-Clinical Trials Unit ( Site 0110)
-
-
New Brunswick
-
Moncton, New Brunswick, Canada, E1C 6Z8
- The Moncton Hospital ( Site 0101)
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0114)
-
Kingston, Ontario, Canada, K7L 2V7
- Kingston Health Sciences Centre ( Site 0105)
-
Ottawa, Ontario, Canada, K1H 8L6
- The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0116)
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0113)
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- CISSS de la Monteregie-Centre ( Site 0103)
-
Québec, Quebec, Canada, G1J 1Z4
- Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0115)
-
Sherbrooke, Quebec, Canada, J1H 5N4
- CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0102)
-
-
-
-
Araucania
-
Temuco, Araucania, Chili, 4800827
- James Lind Centro de Investigacion del Cancer ( Site 0402)
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chili, 8420383
- Bradfordhill-Clinical Area ( Site 0400)
-
-
-
-
Antioquia
-
Medellín, Antioquia, Colombie, 050030
- Fundacion Colombiana de Cancerología Clinica Vida ( Site 0505)
-
-
Cesar Department
-
Valledupar, Cesar Department, Colombie, 200001
- Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 0508)
-
-
Cundinamarca
-
Bogotá, Cundinamarca, Colombie, 111511
- Instituto Nacional de Cancerología-Clinical Oncology ( Site 0500)
-
-
Santander Department
-
Piedecuesta, Santander Department, Colombie, 681017
- Fundación Cardiovascular de Colombia ( Site 0501)
-
-
-
-
-
Seoul, Corée du Sud, 05505
- Asan Medical Center ( Site 4200)
-
Seoul, Corée du Sud, 06351
- Samsung Medical Center ( Site 4201)
-
-
Jeonranamdo
-
Hwasun, Jeonranamdo, Corée du Sud, 58128
- Chonnam National University Hwasun Hospital-Oncology ( Site 4203)
-
-
-
-
-
Barcelona, Espagne, 08035
- Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1507)
-
Barcelona, Espagne, 08036
- Hospital Clinic i Provincial ( Site 1500)
-
Barcelona, Espagne, 08041
- Hospital Santa Creu i Sant Pau ( Site 1501)
-
Madrid, Espagne, 28009
- Hospital General Universitario Gregorio Maranon ( Site 1505)
-
Madrid, Espagne, 28040
- Hospital Clinico San Carlos... ( Site 1504)
-
Seville, Espagne, 41013
- Hospital Virgen del Rocio ( Site 1503)
-
-
La Coruna
-
A Coruña, La Coruna, Espagne, 15006
- Complejo Hospitalario Universitario A Coruna ( Site 1502)
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Espagne, 28041
- Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1508)
-
-
-
-
Pirkanmaa
-
Tampere, Pirkanmaa, Finlande, 33520
- Tampereen yliopistollinen sairaala ( Site 1801)
-
-
Southwest Finland
-
Turku, Southwest Finland, Finlande, 20520
- TYKS ( Site 1802)
-
-
Uusimaa
-
Helsinki, Uusimaa, Finlande, 00290
- HYKS ( Site 1800)
-
-
-
-
-
Paris, France, 75020
- Hopital Tenon ( Site 1213)
-
-
Ain
-
Reims, Ain, France, 51726
- Institut Jean Godinot ( Site 1216)
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, France, 06189
- Centre Antoine Lacassagne ( Site 1217)
-
-
Bas-Rhin
-
Strasbourg, Bas-Rhin, France, 67200
- Hopitaux Universitaires de Strasbourg- Hopital de Hautepierre ( Site 1218)
-
-
Gironde
-
Bordeaux, Gironde, France, 33000
- CHU de Bordeaux- Hopital Saint Andre ( Site 1209)
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, France, 31059
- Institut Claudius Regaud ( Site 1215)
-
-
Haute-Vienne
-
Limoges, Haute-Vienne, France, 87039
- Clinique Francois Chenieux ( Site 1210)
-
-
Loire-Atlantique
-
Saint-Herblain, Loire-Atlantique, France, 44805
- Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 1201)
-
-
Maine-et-Loire
-
Angers, Maine-et-Loire, France, 49055
- Institut de Cancerologie de l Ouest Site Paul Papin ( Site 1200)
-
-
-
-
-
Thessaloniki, Grèce, 570 01
- European Interbalkan Medical Center-Oncology Department ( Site 3300)
-
-
Achaia
-
Pátrai, Achaia, Grèce, 26504
- UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 3302)
-
-
Attica
-
Athens, Attica, Grèce, 115 28
- Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 3304)
-
Athens, Attica, Grèce, 151 25
- Athens Medical Center ( Site 3303)
-
Chaïdári, Attica, Grèce, 124 62
- ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 3301)
-
-
-
-
-
Dublin, Irlande, D24NR0A
- Tallaght University Hospital ( Site 3200)
-
Dublin, Irlande, D07 R2WY
- Mater Misericordiae University Hospital ( Site 3201)
-
Dublin, Irlande, D07 R2WY
- Mater Private Hospital - Dublin ( Site 3202)
-
-
-
-
-
Arezzo, Italie, 52100
- Medical Oncology Ospedale San Donato ( Site 1404)
-
Bari, Italie, 70124
- Azienda Ospedaliera Policlinico di Bari ( Site 1402)
-
Milan, Italie, 20132
- IRCCS Ospedale San Raffaele ( Site 1409)
-
Milan, Italie, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1400)
-
Pavia, Italie, 27100
- Istituti Clinici Scientifici Maugeri Spa ( Site 1403)
-
Roma, Italie, 00168
- Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1410)
-
Terni, Italie, 05100
- Azienda Ospedaliera S. Maria di Terni ( Site 1401)
-
Verona, Italie, 37126
- Ospedale Maggiore Borgo Trento ( Site 1408)
-
-
Forli-Cesena
-
Meldola, Forli-Cesena, Italie, 47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1407)
-
-
Milano
-
Rozzano, Milano, Italie, 20089
- Istituto Clinico Humanitas Research Hospital ( Site 1406)
-
-
Torino
-
Orbassano, Torino, Italie, 10043
- Ospedale San Luigi Gonzaga ( Site 1405)
-
-
-
-
-
Fukuoka, Japon, 812-8582
- Kyushu University Hospital ( Site 5005)
-
Niigata, Japon, 951-8520
- Niigata University Medical & Dental Hospital ( Site 5013)
-
Osaka, Japon, 541-8567
- Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 5016)
-
Tokyo, Japon, 113-8603
- Nippon Medical School Hospital ( Site 5006)
-
Tokyo, Japon, 123-8558
- Tokyo Women's Medical University Adachi Medical Center ( Site 5015)
-
Tokyo, Japon, 160-8582
- Keio University Hospital ( Site 5011)
-
-
Aichi-ken
-
Toyoake, Aichi-ken, Japon, 470-1192
- Fujita Health University Hospital ( Site 5003)
-
-
Chiba
-
Kashiwa, Chiba, Japon, 2778577
- National Cancer Center Hospital East ( Site 5000)
-
Sakura, Chiba, Japon, 285-8741
- Toho University Sakura Medical Center ( Site 5014)
-
-
Hokkaido
-
Sapporo, Hokkaido, Japon, 060-8543
- Sapporo Medical University Hospital ( Site 5008)
-
-
Hyōgo
-
Kobe, Hyōgo, Japon, 650-0047
- Kobe City Medical Center General Hospital ( Site 5017)
-
-
Kanagawa
-
Yokohama, Kanagawa, Japon, 236-0004
- Yokohama City University Hospital ( Site 5007)
-
-
Nara
-
Kashihara, Nara, Japon, 634-0813
- Nara Medical University Hospital ( Site 5002)
-
-
Osaka
-
Sakai, Osaka, Japon, 590-0197
- Kindai University Hospital ( Site 5010)
-
Suita, Osaka, Japon, 565-0871
- The University of Osaka Hospital ( Site 5012)
-
-
Shizuoka
-
Hamamatsu, Shizuoka, Japon, 431-3192
- Hamamatsu University Hospital ( Site 5004)
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japon, 113-8510
- Institute of Science Tokyo Hospital ( Site 5009)
-
Minato-ku, Tokyo, Japon, 105-8470
- Toranomon Hospital ( Site 5001)
-
-
-
-
-
Vienna, L'Autriche, 1020
- Krankenhaus der Barmherzigen Brüder Wien ( Site 1041)
-
Vienna, L'Autriche, 1090
- Medizinische Universität Wien ( Site 1021)
-
-
State of Vienna
-
Vienna, State of Vienna, L'Autriche, 1160
- Klinik Ottakring-1.Medizinische Abteilung - Zentrum für Onkologie und Hämatologie ( Site 1031)
-
-
Styria
-
Graz, Styria, L'Autriche, 8036
- Medizinische Universitätsklinik Graz ( Site 1051)
-
-
Upper Austria
-
Linz, Upper Austria, L'Autriche, 4020
- Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 1001)
-
-
-
-
-
Utrecht, Pays-Bas, 3584 CX
- Universitair Medisch Centrum Utrecht ( Site 1910)
-
-
Limburg
-
Sittard-Geleen, Limburg, Pays-Bas, 6162 BG
- Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1904)
-
-
North Brabant
-
Breda, North Brabant, Pays-Bas, 4818 CK
- Amphia Hospital Location Molengracht ( Site 1912)
-
-
North Holland
-
Amsterdam, North Holland, Pays-Bas, 1066 CX
- Antoni van Leeuwenhoek Ziekenhuis ( Site 1901)
-
-
Provincie Friesland
-
Leeuwarden, Provincie Friesland, Pays-Bas, 8934 AD
- Medisch Centrum Leeuwarden ( Site 1905)
-
-
South Holland
-
Rotterdam, South Holland, Pays-Bas, 3015 GD
- Erasmus MC ( Site 1913)
-
Schiedam, South Holland, Pays-Bas, 3118 JH
- Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1909)
-
The Hague, South Holland, Pays-Bas, 2545 AA
- Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1917)
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Pologne, 60-569
- Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 2401)
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Pologne, 85-796
- Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 2402)
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Pologne, 31-115
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - O-Klinika Onkologii Klinicznej ( Site 2403)
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Pologne, 02-781
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2400)
-
-
-
-
Cluj
-
Cluj-Napoca, Cluj, Roumanie, 400015
- Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2500)
-
Cluj-Napoca, Cluj, Roumanie, 400015
- Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2501)
-
-
Dolj
-
Craiova, Dolj, Roumanie, 200542
- Centrul de Oncologie "Sfântul Nectarie" ( Site 2502)
-
-
-
-
Aberdeen City
-
Aberdeen, Aberdeen City, Royaume-Uni, AB25 2ZN
- Aberdeen Royal Infirmary-Department of Oncology ( Site 3105)
-
-
Bath And North East Somerset
-
Bath, Bath And North East Somerset, Royaume-Uni, BA1 3NG
- Royal United Hospital Bath England ( Site 3108)
-
-
England
-
Nottingham, England, Royaume-Uni, NG5 1PF
- Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 3106)
-
-
Essex
-
Southend, Essex, Royaume-Uni, SS0 0RY
- Southend University Hospital ( Site 3112)
-
-
London, City of
-
London, London, City of, Royaume-Uni, W6 8RF
- Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 3107)
-
Northwood, London, City of, Royaume-Uni, HA6 2RN
- Mount Vernon Cancer Centre ( Site 3101)
-
-
Somerset
-
Taunton, Somerset, Royaume-Uni, TA1 5DA
- Musgrove Park Hospital ( Site 3103)
-
-
Wales
-
Swansea, Wales, Royaume-Uni, SA2 8QA
- Singleton Hospital ( Site 3111)
-
-
-
-
Ivanovo Oblast
-
Ivanovo, Ivanovo Oblast, Russie, 153040
- Ivanovo Regional Oncology Dispensary ( Site 2616)
-
-
Moscow
-
Moscow, Moscow, Russie, 119285
- FSBI United Hospital with Polyclinic ( Site 2613)
-
Moscow, Moscow, Russie, 125130
- SHI of Moscow City Oncology Clinical Hospital - 62 ( Site 2614)
-
-
Moscow Oblast
-
Krasnogorsk, Moscow Oblast, Russie, 143442
- MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 2618)
-
Moscow, Moscow Oblast, Russie, 121205
- Hadassah Medical-Oncology department ( Site 2609)
-
-
Volgograd Oblast
-
Volzhsky, Volgograd Oblast, Russie, 404120
- Volgograd Regional Uronephrological Center ( Site 2615)
-
-
Yaroslavl Oblast
-
Yaroslavl, Yaroslavl Oblast, Russie, 150054
- Yaroslavl Regional Cancer Hospital-Oncology ( Site 2619)
-
-
-
-
Canton Ticino
-
Bellinzona, Canton Ticino, Suisse, 6500
- Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1604)
-
-
Canton of Geneva
-
Geneva, Canton of Geneva, Suisse, 1211
- Hopitaux Universitaires de Geneve HUG ( Site 1602)
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, Suisse, 8001
- Universitaetsspital Zuerich ( Site 1601)
-
-
Kanton Graubünden
-
Chur, Kanton Graubünden, Suisse, 7000
- Kantonsspital Graubuenden ( Site 1600)
-
-
-
-
-
Hradec Králové, Tchéquie, 500 05
- Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 2201)
-
-
Brno-mesto
-
Brno, Brno-mesto, Tchéquie, 656 53
- Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 2203)
-
-
Praha 4
-
Prague, Praha 4, Tchéquie, 140 59
- Fakultni Thomayerova nemocnice-Onkologicka klinika 1. LF UK ( Site 2200)
-
-
Praha 5
-
Prague, Praha 5, Tchéquie, 150 06
- Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 2205)
-
-
South Bohemian Region
-
České Budějovice, South Bohemian Region, Tchéquie, 37001
- Nemocnice Ceske Budejovice-Onkologicke oddeleni ( Site 2204)
-
-
-
-
Arizona
-
Chandler, Arizona, États-Unis, 85224
- Ironwood Cancer & Research Centers ( Site 0077)
-
-
California
-
Los Angeles, California, États-Unis, 90048
- Cedars Sinai Medical Center ( Site 0027)
-
Los Angeles, California, États-Unis, 90404
- UCLA Hematology/Oncology - Santa Monica ( Site 0048)
-
Orange, California, États-Unis, 92868
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095)
-
Orange, California, États-Unis, 92868
- University of California, Irvine ( Site 0029)
-
Santa Monica, California, États-Unis, 90404
- Providence Saint John's Health Center ( Site 0083)
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20007
- Georgetown University Medical Center ( Site 0006)
-
-
Florida
-
Orlando, Florida, États-Unis, 32806
- Orlando Health, Inc. ( Site 0035)
-
Orlando, Florida, États-Unis, 32804
- AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0003)
-
-
Georgia
-
Athens, Georgia, États-Unis, 30607
- University Cancer & Blood Center, LLC ( Site 0057)
-
Atlanta, Georgia, États-Unis, 30322
- Emory University Hospital ( Site 0012)
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60607
- Rush University Medical Center ( Site 0040)
-
Peoria, Illinois, États-Unis, 61615
- Illinois Cancer Care, PC ( Site 0008)
-
-
Indiana
-
Fort Wayne, Indiana, États-Unis, 46845
- Parkview Cancer Institute ( Site 0088)
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40207
- Norton Cancer Institute - St. Matthews ( Site 0065)
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 70112
- Tulane University School of Medicine ( Site 0098)
-
-
Massachusetts
-
Burlington, Massachusetts, États-Unis, 01805
- Lahey Hospital & Medical Center ( Site 0090)
-
-
Michigan
-
Grand Rapids, Michigan, États-Unis, 49503
- Cancer & Hematology Centers of Western Michigan ( Site 0018)
-
-
Minnesota
-
Saint Louis Park, Minnesota, États-Unis, 55426
- HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005)
-
-
Mississippi
-
Jackson, Mississippi, États-Unis, 39213
- University of Mississippi Medical Ctr ( Site 0037)
-
-
Nebraska
-
Lincoln, Nebraska, États-Unis, 68516
- Cancer Partners of Nebraska ( Site 0086)
-
-
New Jersey
-
New Brunswick, New Jersey, États-Unis, 08903
- Rutgers Cancer Institute of New Jersey ( Site 0078)
-
-
New York
-
Lake Success, New York, États-Unis, 11042
- R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013)
-
New York, New York, États-Unis, 10065
- Memorial Sloan Kettering Cancer Center ( Site 0055)
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28204
- Levine Cancer Institute ( Site 0004)
-
Durham, North Carolina, États-Unis, 27710
- Duke Cancer Institute ( Site 0096)
-
-
Pennsylvania
-
Allentown, Pennsylvania, États-Unis, 18103
- Lehigh Valley Hospital- Cedar Crest-Oncology Clinical Trials ( Site 0056)
-
-
Texas
-
Dallas, Texas, États-Unis, 75235
- University of Texas, Southwestern Medical Center ( Site 0015)
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112
- Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 7001)
-
-
Vermont
-
Burlington, Vermont, États-Unis, 05401
- University of Vermont Medical Center ( Site 0001)
-
-
Virginia
-
Roanoke, Virginia, États-Unis, 24014
- Blue Ridge Cancer Care - Roanoke ( Site 0043)
-
-
Washington
-
Seattle, Washington, États-Unis, 98109
- Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 0093)
-
Wenatchee, Washington, États-Unis, 98801
- Central Washington Health Services Association d/b/a Confluence Health ( Site 0061)
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC)
- Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1) therapy as either first or second-line treatment for locally advanced/metastatic RCC or as adjuvant treatment or neoadjuvant/adjuvant with progression on or within 6 months of last dose
- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria as assessed by local study investigator
- Karnofsky performance status (KPS) score of at least 70% assessed within 10 days before randomization
- Received no more than 2 prior systemic regimens including: one anti-PD-1/L1 containing adjuvant or neoadjuvant/adjuvant regimens with progression on or within 6 months from the last dose of that regimen OR one or 2 regimens for locoregional/advanced disease
- Received only 1 prior antiPD-1/L1 therapy for adjuvant, neoadjuvant/adjuvant or locally advanced/metastatic RCC
- A male participant is eligible to participate if he is abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 7 days after the last dose of belzutifan or lenvatinib in the belzutifan+lenvatinib arm, whichever occurs last, and 23 days after the last dose of cabozantinib
- A female participant is eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 30 days after the last dose of study intervention in the belzutifan+ lenvatinib arm, or 120 days after the last dose of study intervention in the cabozantinib arm
- Adequately controlled blood pressure
- Adequate organ function
Exclusion Criteria:
- A pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
- Known additional malignancy that is progressing or has required active treatment within the past 3 years except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy
- Known central nervous system (CNS) metastases and/or carcinomatous meningitis
- Clinically significant cardiac disease within 6 months of first dose of study intervention
- Prolongation of corrected QT interval (QTc) interval to >480 ms.
- Symptomatic pleural effusion (e.g.,cough, dyspnea, pleuritic chest pain) that is not clinically stable
- Pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula.
- Moderate to severe hepatic impairment
- History of significant bleeding within 3 months before randomization.
- History of solid organ transplantation
- Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study
- Unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption)
- Known hypersensitivity or allergy to the active pharmaceutical ingredients or any component of the study intervention formulations
- Received colony-stimulating factors [eg, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant erythropoietin (EPO)] within 28 days before randomization
- Prior treatment with belzutifan or another hypoxia-inducible factor (HIF)-2α inhibitor
- Prior treatment with lenvatinib
- Prior treatment with cabozantinib
- Currently participating in a study of an investigational agent or using an investigational device
- Active infection requiring systemic therapy
- History of human immunodeficiency virus (HIV) infection
- History of hepatitis B or known active hepatitis C infection
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Belzutifan + Lenvatinib
Participants received daily oral dose of belzutifan 120 mg and lenvatinib 20 mg until progressive disease or discontinuation. |
Oral administration
Autres noms:
Oral administration
Autres noms:
|
|
Comparateur actif: Cabozantinib
Participants received daily oral dose of cabozantinib 60 mg until progressive disease or discontinuation. |
Oral administration
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Délai: Up to approximately 34 months
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review will be presented. |
Up to approximately 34 months
|
|
Overall Survival (OS)
Délai: Up to approximately 44 months
|
OS is defined as time from randomization to death due to any cause. |
Up to approximately 44 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Délai: Up to approximately 24 months
|
ORR is defined as the percentage of participants who have a complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 will be presented. |
Up to approximately 24 months
|
|
Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Délai: Up to approximately 44 months
|
For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. The DOR as assessed by blinded independent central review will be presented. |
Up to approximately 44 months
|
|
Number of Participants Who Experienced One or More Adverse Events (AEs)
Délai: Up to approximately 44 months
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 44 months
|
|
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
Délai: Up to approximately 44 months
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 44 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Directeur d'études: Medical Director, Merck Sharp & Dohme LLC
Publications et liens utiles
Publications générales
- Motzer RJ, Schmidinger M, Eto M, Suarez C, Figlin R, Liu Y, Perini R, Zhang Y, Heng DY. LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncol. 2023 Jan;19(2):113-121. doi: 10.2217/fon-2022-0802. Epub 2023 Feb 8.
- Motzer RJ, McDermott R, Park SH, Burotto M, Iacovelli R, Verzoni E, Suarez C, Eto M, Cutuli HJ, Porta C, Kopp RM, Rottey S, Velasco G, Valderrama BP, Azad AA, Giorgi U, Pavic M, Tomczak P, Figlin R, Westgeest HM, Guida A, Necchi A, Schutz FA, Suelmann BBM, Haanen JBAG, Yuan SS, Perini RF, Wang D, Heng DYC, Schmidinger M; LITESPARK-011 Investigators. Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. Lancet. 2026 Aug 12:S0140-6736(26)01089-5. doi: 10.1016/S0140-6736(26)01089-5. Online ahead of print.
- Heng DYC, Schmidinger M, McDermott R, Park SH, Burotto M, Ciccarese C, Verzoni E, Suarez C, Eto M, Cutuli HJ, Porta C, Kopp RM, Rottey S, de Velasco G, Valderrama BP, Azad AA, De Giorgi U, Pavic M, Tomczak P, Figlin R, Westgeest HM, Guida A, Necchi A, Schutz FA, Suelmann BBM, Haanen JB, Lin J, Perini RF, Vickery D, Motzer RJ; LITESPARK-011 Investigators. Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti-PD-(L)1 therapy. Ann Oncol. 2026 Oct 25:S0923-7534(26)06893-6. doi: 10.1016/j.annonc.2026.10.109. Online ahead of print.
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs
- Maladies urogénitales masculines
- Maladies rénales
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Tumeurs par type histologique
- Tumeurs, glandulaires et épithéliales
- Adénocarcinome
- Tumeurs urologiques
- Carcinome
- Tumeurs rénales
- Carcinome à cellules rénales
- cabozantinib
- belzutifan
- lenvatinib
Autres numéros d'identification d'étude
- 6482-011
- MK-6482-011 (Autre identifiant: MSD)
- jRCT2031210311 (Autre identifiant: jRCT(Japan Registry of Clinical Trials))
- 2020-002075-35 (Numéro EudraCT)
- U1111-1302-2815 (Identificateur de registre: UTN)
- 2024-510620-39-00 (Identificateur de registre: EU CT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .